相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer
Teresa Hemmerle et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization
Andrea Weiss et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
IL-4 reduces the proangiogenic capacity of macrophages by down-regulating HIF-1α translation
Nathalie Dehne et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2014)
Metronomics: towards personalized chemotherapy?
Nicolas Andre et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo
Petra Heffeter et al.
EUROPEAN JOURNAL OF CANCER (2013)
Photodynamic therapeutic effect of indocyanine green entrapped in polymeric nanoparticles and their anti-EGFR-conjugate in skin cancer in CD1 mice
Amira M. Gamal-Eldeen et al.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY (2013)
Photodynamic therapy for polypoidal choroidal vasculopathy
Patrycja Nowak-Sliwinska et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2013)
Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia
Katrin L. Gutbrodt et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer
Giampietro Gasparini et al.
ANGIOGENESIS (2012)
Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity
Emilia Montagna et al.
CLINICAL BREAST CANCER (2012)
Combining angiogenesis inhibition and radiotherapy: A double-edged sword
Esther A. Kleibeuker et al.
DRUG RESISTANCE UPDATES (2012)
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion
Patrycja Nowak-Sliwinska et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study
Teresa M. Petrella et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Photodiagnosis and photodynamic therapy of peritoneal metastasis of ovarian cancer
Laurie Guyon et al.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY (2012)
The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer
Michael Eichbaum et al.
BMC CANCER (2011)
Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration
F. Fan et al.
BRITISH JOURNAL OF CANCER (2011)
Photodynamic Therapy of Cancer: An Update
Patrizia Agostinis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Enhancement of T-cell-Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer
Ruud P. M. Dings et al.
CLINICAL CANCER RESEARCH (2011)
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
Kristy J. Gotink et al.
CLINICAL CANCER RESEARCH (2011)
Quantitative Model for Efficient Temporal Targeting of Tumor Cells and Neovasculature
M. Kohandel et al.
COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE (2011)
Combination photodynamic therapy and intravitreal bevacizumab used to treat circumscribed choroidal hemangioma
Chih-Chien Hsu et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2011)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
ROBUSTNESS OF OPTIMAL CONTROLS FOR A CLASS OF MATHEMATICAL MODELS FOR TUMOR ANTI-ANGIOGENESIS
Heinz Schaettler et al.
MATHEMATICAL BIOSCIENCES AND ENGINEERING (2011)
Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane
Patrycja Nowak-Sliwinska et al.
ANGIOGENESIS (2010)
Toxicity of Sunitinib Plus Bevacizumab in Renal Cell Carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer
Hop S. Tran Cao et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
Kae Hashimoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
TARGETED THERAPIES Sunitinib versus interferon-alpha in metastatic RCC
Jason E. Faris et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Low Doses of Ionizing Radiation Promote Tumor Growth and Metastasis by Enhancing Angiogenesis
Ines Sofia Vala et al.
PLOS ONE (2010)
Photodynamic therapy in dermatology: state-of-the-art
Philipp Babilas et al.
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE (2010)
A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
Brian I. Rini et al.
CLINICAL CANCER RESEARCH (2009)
Coexpression of IL-18 Strongly Attenuates IL-12-Induced Systemic Toxicity through a Rapid Induction of IL-10 without Affecting its Antitumor Capacity
Maria Cecilia Rodriguez-Galan et al.
JOURNAL OF IMMUNOLOGY (2009)
Angiostatin anti-angiogenesis requires IL-12: The innate immune system as a key target
Adriana Albini et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation
Ruslan Hlushchuk et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Angiostatic activity of the antitumor cytokine interleukin-21
Karolien Castermans et al.
BLOOD (2008)
KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
Christian G. Hartinger et al.
CHEMISTRY & BIODIVERSITY (2008)
A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118)
Jonathan P. S. Knisely et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer
Tanguy Y. Seiwert et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines
Ene T. Raig et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2008)
Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization
Ruud P. M. Dings et al.
CLINICAL CANCER RESEARCH (2007)
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results
Brian G. Czito et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis
Michael I. Dorrell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model
A Ferrario et al.
JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY (2006)
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: Evidence for modulation of interferon signaling pathways by interleukin-12
CF Eisenbeis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
DF McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent
JM Rademaker-Lakhai et al.
CLINICAL CANCER RESEARCH (2004)
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma
JA Gollob et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
G Klement et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
